✦ LIBER ✦

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma

✍ Scribed by Gaston, R; Oskam, R; Philip, T; Ravaud, A; Négrier, S; Cany, L; Merrouche, Y; Le Guillou, M; Blay, JY; Clavel, M

Book ID: 109836994
Publisher: Nature Publishing Group
Year: 1994
Tongue: English
Weight: 876 KB
Volume: 69
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1994.218

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of interferon α and low

A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma

✍ A. Piga; Paolo Giordani; Agata Quattrone; Marco Giulioni; Giorgio De Signoribus; 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 72 KB

Outpatient treatment with subcutaneous i

Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

✍ G. Marx; J. Taylor; D. Goldstein 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Metastatic renal-cell carcinoma patients

Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

✍ Françoisc Farace; Marc Pallardy; Eric Angevin; Thierry Hercend; Bernard Escudier 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 737 KB

## Abstract We investigated the biological response of 73 patients with metastatic renal‐cell carcinoma (MRCC) treated by repetitive weekly cycles of high‐dose interleukin 2 (IL‐2) (protocol 1, 40 patients) or IL‐2 plus interferon‐gamma (IFN‐γ) (protocol 2, 33 patients). The objectives of this stud

Cytotoxic In vitro function in patients

Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2

✍ Cristina Feruglio; Renato Zambello; Livio Trentin; Pietro Bulian; Tiziano France 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Serum interferon alpha receptor 2 mRNA m

Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma

✍ Nobutaka Furuya; Takao Kamai; Hiromichi Shirataki; Yoshiaki Yanai; Takehiko Fuku 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 896 KB

Interferon-alpha antibodies in patients

Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial

✍ Otto Prümmer; Delta-P Study Group 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 657 KB

Background. Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies. Methods. Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-a2a